Literature DB >> 29744574

Past and prognosis of anti-VEGF therapy for wet age-related macular degeneration-the future has begun.

Justus G Garweg1,2, J J Zirpel3, C Gerhardt4,3, Isabel B Pfister4,3.   

Abstract

Entities:  

Year:  2018        PMID： 29744574     DOI： 10.1007/s00417-018-4005-x

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  27 in total

Review 1.  Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients.

Authors:  David M Brown; Carl D Regillo
Journal:  Am J Ophthalmol       Date:  2007-10       Impact factor: 5.258

2.  Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial.

Authors:  Charles C Wykoff; William C Ou; Daniel E Croft; John F Payne; David M Brown; W Lloyd Clark; Nizar Saleh Abdelfattah; SriniVas R Sadda
Journal:  Br J Ophthalmol       Date:  2017-08-04       Impact factor: 4.638

3.  Comparison of Strategies of Treatment with Ranibizumab in Newly-Diagnosed Cases of Neovascular Age-Related Macular Degeneration.

Authors:  Justus G Garweg; Sophie A Niderprim; Hanna Maria Russ; Isabel B Pfister
Journal:  J Ocul Pharmacol Ther       Date:  2017-09-27       Impact factor: 2.671

4.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

5.  The Clinical Importance of Changes in Diabetic Retinopathy Severity Score.

Authors:  Michael S Ip; Jiameng Zhang; Jason S Ehrlich
Journal:  Ophthalmology       Date:  2017-03-08       Impact factor: 12.079

6.  Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study.

Authors:  Frank G Holz; Winfried Amoaku; Juan Donate; Robyn H Guymer; Ulrich Kellner; Reinier O Schlingemann; Andreas Weichselberger; Giovanni Staurenghi
Journal:  Ophthalmology       Date:  2011-04       Impact factor: 12.079

Review 7.  New Treatment Modalities for Neovascular Age-Related Macular Degeneration.

Authors:  Patricio G Schlottmann; Arturo A Alezzandrini; Marcelo Zas; Francisco J Rodriguez; José D Luna; Lihteh Wu
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2017-09-14

Review 8.  Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).

Authors:  Ursula Schmidt-Erfurth; Victor Chong; Anat Loewenstein; Michael Larsen; Eric Souied; Reinier Schlingemann; Bora Eldem; Jordi Monés; Gisbert Richard; Francesco Bandello
Journal:  Br J Ophthalmol       Date:  2014-09       Impact factor: 4.638

Review 9.  Individualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?

Authors:  Michael W Stewart
Journal:  J Clin Med       Date:  2015-05-21       Impact factor: 4.241

10.  Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study.

Authors:  Frank G Holz; Ramin Tadayoni; Stephen Beatty; Alan Berger; Matteo Giuseppe Cereda; Philip Hykin; Giovanni Staurenghi; Kim Wittrup-Jensen; Andreas Altemark; Jonas Nilsson; Kun Kim; Sobha Sivaprasad
Journal:  Br J Ophthalmol       Date:  2016-03-30       Impact factor: 4.638
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.